ATE261982T1 - Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon - Google Patents

Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon

Info

Publication number
ATE261982T1
ATE261982T1 AT98937115T AT98937115T ATE261982T1 AT E261982 T1 ATE261982 T1 AT E261982T1 AT 98937115 T AT98937115 T AT 98937115T AT 98937115 T AT98937115 T AT 98937115T AT E261982 T1 ATE261982 T1 AT E261982T1
Authority
AT
Austria
Prior art keywords
sub
treatment
tetraphosphate
uridine
salts
Prior art date
Application number
AT98937115T
Other languages
English (en)
Inventor
Benjamin R Yerxa
William Pendergast
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE261982T1 publication Critical patent/ATE261982T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98937115T 1997-07-25 1998-07-24 Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon ATE261982T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5414797P 1997-07-25 1997-07-25
PCT/US1998/015445 WO1999005155A2 (en) 1997-07-25 1998-07-24 Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof

Publications (1)

Publication Number Publication Date
ATE261982T1 true ATE261982T1 (de) 2004-04-15

Family

ID=21989063

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98937115T ATE261982T1 (de) 1997-07-25 1998-07-24 Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon

Country Status (16)

Country Link
US (1) US7432252B1 (de)
EP (1) EP1012154B1 (de)
JP (1) JP3723227B2 (de)
KR (1) KR20010013797A (de)
CN (1) CN1147502C (de)
AT (1) ATE261982T1 (de)
AU (1) AU747196B2 (de)
BR (1) BRPI9810436B1 (de)
CA (1) CA2295515C (de)
DE (1) DE69822482T2 (de)
DK (1) DK1012154T3 (de)
ES (1) ES2217569T3 (de)
NO (1) NO328229B1 (de)
NZ (1) NZ501696A (de)
PT (1) PT1012154E (de)
WO (1) WO1999005155A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
EP1012154B1 (de) 1997-07-25 2004-03-17 Inspire Pharmaceuticals, Inc. Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
US6462028B2 (en) * 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
EP1043329B1 (de) * 1998-10-02 2002-08-28 Yamasa Corporation Ein kristall von diuridine tetraphosphat oder ein solches salz und verfahren zu seiner herstellung, verfahren und herstellung der vorgenannten zusammensetzung
CN100354296C (zh) * 1998-10-02 2007-12-12 雅玛山酱油株式会社 二尿苷四磷酸或其盐的晶体和其制备方法、以及制备该化合物的方法
BR0012205A (pt) 1999-06-30 2002-05-28 Yamasa Corp Cristais de dinucleótido
WO2001056581A1 (en) * 2000-02-04 2001-08-09 Kissei Pharmaceutical Co., Ltd. Powdered preparation for inhalation and powder inhalant containing the same packed
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
CN1228053C (zh) * 2001-09-11 2005-11-23 参天制药株式会社 含有二尿苷磷酸的滴眼液
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
CN101495497B (zh) 2006-07-26 2012-03-14 Yamasa酱油株式会社 二(嘧啶核苷5’-)多磷酸的制备方法
JP5599078B2 (ja) * 2009-06-23 2014-10-01 ヤマサ醤油株式会社 アデノシンテトラホスフェート化合物の製造法
PH12013500424B1 (en) 2010-09-10 2018-07-11 Santen Pharmaceutical Co Ltd Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
MY161032A (en) 2010-12-28 2017-04-03 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
CN102146111A (zh) * 2011-01-26 2011-08-10 北京润德康医药技术有限公司 一类新型二核苷酸化合物及其制备方法
MY169816A (en) 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
KR102259309B1 (ko) * 2016-10-25 2021-06-01 야마사 쇼유 가부시키가이샤 P1, p4-디(우리딘 5'-)테트라포스페이트의 정제 방법
KR102504764B1 (ko) * 2017-06-21 2023-03-02 주식회사 종근당 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
CN109305991B (zh) * 2017-07-27 2021-02-26 江苏恒瑞医药股份有限公司 一种p1,p4-二(尿苷5’-)四磷酸钠的制备方法
KR20180091689A (ko) 2017-11-06 2018-08-16 주식회사 종근당 무정형 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
KR102472773B1 (ko) 2018-02-28 2022-11-30 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 및 양이온성 폴리머를 함유하는 안과용 조성물
CN110540555B (zh) * 2018-05-28 2023-01-24 江苏恒瑞医药股份有限公司 一种游离核苷磷酸的方法
CN109021049B (zh) * 2018-06-14 2020-12-08 扬子江药业集团北京海燕药业有限公司 一种尿苷5′-二磷酸-苯并咪唑二钠的合成方法
CN113518646B (zh) 2019-02-27 2023-12-12 参天制药株式会社 含有地夸磷索或其盐，乙烯基系高分子及纤维素系高分子的眼科用组合物
KR20200106738A (ko) 2019-03-05 2020-09-15 주식회사 파마코스텍 P1,p4-디(우리딘 5'-)테트라포스페이트, 이의 염 또는 이의 수화물의 신규한 제조방법
CN110590887B (zh) * 2019-09-04 2020-12-15 江苏金殳医药科技有限公司 一种磷酸酯的制备方法
KR102790402B1 (ko) 2019-12-18 2025-04-03 주식회사 종근당 우리딘 5’-디인산(udp), 이의 염 또는 이의 수화물의 제조방법
KR20210110055A (ko) * 2020-02-28 2021-09-07 주식회사 종근당바이오 P1, p4-디(우리딘 5'-)테트라포스페이트 나트륨염 4 수화물 결정형 a의 제조방법
CN111662350B (zh) * 2020-07-07 2022-06-07 南京宸翔医药研究有限责任公司 一种绿色化智能化高纯度地夸磷索四钠的制备方法
CN114644664A (zh) * 2020-12-18 2022-06-21 齐鲁制药有限公司 一种制备对称双尿苷四磷酸盐的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639562A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US3639561A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
JPH05346549A (ja) 1992-04-17 1993-12-27 Canon Inc 走査光学装置
WO1995010538A1 (en) 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
JP3519199B2 (ja) 1996-02-06 2004-04-12 株式会社ソニー・コンピュータエンタテインメント 画像生成装置
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
CA2250188C (en) * 1996-03-27 2008-12-09 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5837861A (en) 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5962432A (en) 1996-07-03 1999-10-05 Inspire Pharmaceuticals, Inc. Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5968913A (en) 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1998015835A1 (en) 1996-10-08 1998-04-16 Inspire Pharmaceuticals, Inc. Method of early lung cancer detection via sputum induction and analysis of sputum to detect cancer associated substances
US6159952A (en) 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
PT981534E (pt) * 1997-02-06 2006-09-29 Inspire Pharmaceuticals Inc Dinucleotidos e suas utilizacoes
EP1012154B1 (de) 1997-07-25 2004-03-17 Inspire Pharmaceuticals, Inc. Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
AU9124998A (en) 1997-08-29 1999-03-16 Inspire Pharmaceuticals Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung iseases
CN1301168A (zh) 1998-05-22 2001-06-27 印斯拜尔药品股份有限公司 治疗性二核苷酸和衍生物
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
GB9827477D0 (en) 1998-12-15 1999-02-10 Kalon Limited Paint
EP1140967A1 (de) 1998-12-23 2001-10-10 University Of North Carolina At Chapel Hill Gezielter gentransfer unter verwendung von an g-protein gekoppelten rezeptoren
AR023088A1 (es) 1999-02-26 2002-09-04 Inspire Pharmaceuticals Inc Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas.

Also Published As

Publication number Publication date
JP2001510484A (ja) 2001-07-31
JP3723227B2 (ja) 2005-12-07
WO1999005155A2 (en) 1999-02-04
HK1028613A1 (en) 2001-02-23
BRPI9810436B1 (pt) 2015-12-29
DK1012154T3 (da) 2004-07-26
NO996189L (no) 2000-03-27
EP1012154A2 (de) 2000-06-28
NZ501696A (en) 2001-08-31
CA2295515A1 (en) 1999-02-04
AU747196B2 (en) 2002-05-09
CA2295515C (en) 2006-03-14
NO328229B1 (no) 2010-01-11
PT1012154E (pt) 2004-08-31
CN1265114A (zh) 2000-08-30
EP1012154B1 (de) 2004-03-17
DE69822482T2 (de) 2005-03-03
AU8590398A (en) 1999-02-16
WO1999005155A3 (en) 1999-06-24
BR9810436A (pt) 2000-12-12
DE69822482D1 (de) 2004-04-22
US7432252B1 (en) 2008-10-07
ES2217569T3 (es) 2004-11-01
CN1147502C (zh) 2004-04-28
KR20010013797A (ko) 2001-02-26
NO996189D0 (no) 1999-12-14

Similar Documents

Publication Publication Date Title
ATE261982T1 (de) Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
BR9915636A (pt) Método para promover secreções cervicais e vaginais
BR9809562A (pt) Método de tratar doença de secura ocular com agonistas receptores purinérgicos
NZ522326A (en) Adenosine A2A receptor antagonists
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
ATE506372T1 (de) Verfahren zur herstellung von nukleosidderivate
ATE276740T1 (de) Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten
DK1140104T3 (da) Behandling af Alzheimer's sygdom ved forögelse af cytidinniveauer in vivo
LU92425I2 (fr) Dichlorure de radium Ra 2232 et ses dérivés pharmaceutiquement acceptables (XOFIGO®)
TR200201001T2 (tr) Pürin türevleri
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
WO1997035591B1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
BR0112659A (pt) Processo para o tratamento de secura vaginal ou disfunção sexual em mulheres durante ou depois da menopausa e utilização do composto (diaminoidroxi)toremifeno ou de um sal, éster ou metabolito farmaceuticamente aceitável do mesmo
BR0110759A (pt) Métodos para modular o crescimento de uma célula, e para o tratamento e/ ou profilaxia de uma condição distinguida pelo crescimento celular aberrante, indesejável ou de outro modo não apropriado em um mamìfero, uso de um agente capaz de modular a atividade funcional de esfingosina quinase, composição farmacêutica, e, método de diagnose de uma condição, ou uma predisposição ou resistência a uma condição, distinguida pelo crescimento celular aberrante, indesejável, ou de outro modo não apropriado em um mamìfero
WO2001045691A3 (en) Method of treating gastrointestinal tract disease with purinergic receptor agonists
ES2080140T3 (es) Derivados de eritromicina.
BR9811643A (pt) Suplementação quìmica de osso
ATE186732T1 (de) (e)-2'-deoxy-2'-(fluormethylen)cytidin-monohydr t
ATE141796T1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
EP0948967A3 (de) Behandlung einer Virusinfektion bei Schweinen
BR9811422A (pt) Processo para a inibição de hiperplasia celular de músculo liso vascular em um paciente humano ou em outro paciente animal de sangue quente necessitando de tal tratamento, uso de pelo menos um oligossacarìdeo sulfatado, e, composição farmacêutica ou veterinária para a inibição de hiperplasia celular de músculo liso vascular
IT1251160B (it) Impiego di composti adenosinici nel trattamento dell'ischemia
AP2004003082A0 (en) Pharmaceutical combinations of adenosine A-2A and beta-2- adrenergic receptor agonists
ES2176642T3 (es) Utilizacion de la sulbutiamina para la obtencion de composiciones farmaceuticas utiles en el tratamiento de ciertos t rastornos psicomotores y psicointelectuales.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1012154

Country of ref document: EP